A second and final part of the study will evaluate selected dose regimens chosen based on part 1 JERUSALEM , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has completed the first part of the PK/PD study in hypoparathyroidism patients with its oral

JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ) (NASDAQ: ENTXW ), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics, announced today the pricing of its initial public offering of